

# Registration is now open for Oligonucleotide Therapeutics and Delivery Conference

*SAE Media Group reports: The Oligonucleotide Therapeutics & Delivery Conference returns in September 2022*

LONDON, NON UNITED STATES OR CANADA, UNITED KINGDOM, May 10, 2022 /EINPresswire.com/ -- SAE Media Group is delighted to announce the 2nd Annual Conference

[Oligonucleotide](#) Therapeutics & Delivery, taking place on the 21st and 22nd September 2022 in London, UK. The 2022 Conference theme is on the latest advances in oligonucleotide discovery and delivery.

Chairs for the conference are industry expert Ekkehard Leberer, Senior Consultant, Elbiocon, and Jim Weterings, Principal Scientist, AstraZeneca.

Also taking place is the Oligonucleotide Therapeutics & Delivery two interactive Workshops on the 20th September 2022.

Interested parties can register for the conference and workshop at: <http://www.oligonucleotide.co.uk/PR1EIN> and take advantage of the early bird offer to save £300 which expires 31st May 2022.

By attending the conference attendees will have the opportunity to

- Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
- Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity



- Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
- Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
- Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics

Building on the success of previous years of the RNA Portfolio, the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference will bring together industry experts from big pharma and leading biotechs to gain an expert and holistic view on the latest developments of the industry.

View the agenda and speaker line – up at <http://www.oligonucleotide.co.uk/PR1EIN>

For sponsorship enquiries contact Luke Teachen on +44 (0) 20 7827 6002 or email: [lteachen@smi-online.co.uk](mailto:lteachen@smi-online.co.uk)

For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email [ngaloria@smi-online.co.uk](mailto:ngaloria@smi-online.co.uk)

Oligonucleotide Therapeutics & Delivery Conference  
21-22 September 2022  
London, UK  
#OligoTx  
<http://www.oligonucleotide.co.uk/PR1EIN>

--- ENDS ---

About SAE Media Group Conferences:

SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. <http://www.smgconferences.com>

SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

Nikisha Galoria  
SMi Group  
02078276000

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/571811223>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.